{"id":6207,"date":"2026-02-12T16:04:10","date_gmt":"2026-02-12T13:04:10","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=6207"},"modified":"2026-02-12T16:11:13","modified_gmt":"2026-02-12T13:11:13","slug":"satellos-first-participant-dosed-in-phase-2-study-of-sat-3247-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/satellos-first-participant-dosed-in-phase-2-study-of-sat-3247-duchenne-muscular-dystrophy\/","title":{"rendered":"Satellos, Duchenne Kas Distrofisi i\u00e7in Geli\u015ftirilen SAT-3247'nin Faz 2 Pediatrik \u00c7al\u0131\u015fmas\u0131nda \u0130lk Kat\u0131l\u0131mc\u0131n\u0131n Dozunun Verildi\u011fini Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Satellos Bioscience, Duchenne kas distrofisi (&quot;Duchenne&quot; veya &quot;DMD&quot;) i\u00e7in SAT-3247&#039;nin \u00fc\u00e7 ayl\u0131k, randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc, kavram kan\u0131t\u0131 niteli\u011findeki Faz 2 pediatrik \u00e7al\u0131\u015fmas\u0131 olan BASECAMP&#039;te ilk kat\u0131l\u0131mc\u0131ya doz verildi\u011fini duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00e7al\u0131\u015fma, 7, 8 veya 9 ya\u015flar\u0131ndaki, ayakta tedavi g\u00f6ren 51 DMD&#039;li \u00e7ocukta SAT-3247&#039;yi de\u011ferlendirecektir. Birincil de\u011ferlendirme noktalar\u0131 aras\u0131nda g\u00fcvenlik, tolere edilebilirlik ve kas kuvveti \u00fczerindeki etki yer almaktad\u0131r. \u0130kincil de\u011ferlendirme noktalar\u0131 ise SAT-3247&#039;nin kas kalitesi, fonksiyonu ve rejenerasyonu \u00fczerindeki etkisini de\u011ferlendirecektir. <strong>Daha fazla bilgi edin:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/tr\/potential-of-sat-3247-to-restore-muscle-regeneration-in-duchenne-published-in-nature\/\" target=\"_blank\" rel=\"noreferrer noopener\">SAT-3247&#039;nin Duchenne Hastal\u0131\u011f\u0131nda Kas Yenilenmesini Geri Kazand\u0131rma Potansiyeli Nature Dergisinde Yay\u0131mland\u0131<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cSatellos Kurucu Orta\u011f\u0131 ve CEO&#039;su Frank Gleeson, \u201dPotansiyel olarak d\u00f6n\u00fcm noktas\u0131 niteli\u011finde bir \u00e7al\u0131\u015fma olarak tasarlanan BASECAMP, Satellos i\u00e7in Duchenne kas distrofisi olan \u00e7ocuklarda SAT-3247&#039;nin tedavi potansiyelini de\u011ferlendirmede \u00f6nemli bir ad\u0131m te\u015fkil ediyor\u201c dedi. \u201dBASECAMP&#039;ten elde edilen veriler, SAT-3247&#039;nin bu hastal\u0131k i\u00e7in yeni bir tedavi olarak geli\u015ftirilmesini h\u0131zland\u0131rmada anlaml\u0131 bir rol oynayabilir.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">SAT-3247 klinik denemeleri hangi \u00fclkelerde ba\u015flayacak?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>BASECAMP deneyi aktif olarak hasta kayd\u0131na devam ediyor ve Satellos, Amerika Birle\u015fik Devletleri, Avrupa, Birle\u015fik Krall\u0131k, Avustralya, Kanada ve S\u0131rbistan&#039;daki klinik merkezlerde \u00e7al\u0131\u015fma i\u00e7in 25 merkez kurmay\u0131 planl\u0131yor.<\/strong> Devam\u0131n\u0131 oku: <a href=\"https:\/\/dmdwarrior.com\/tr\/how-to-participate-in-clinical-trials-for-duchenne\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u00c7ocu\u011fum Duchenne Klinik Denemelerine Nas\u0131l Kat\u0131labilir?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cSatellos Ba\u015f T\u0131p Sorumlusu Dr. Wildon Farwell, \u201dBASECAMP, Duchenne kas hastal\u0131\u011f\u0131n\u0131n kas sa\u011fl\u0131\u011f\u0131 ve fonksiyonunun daha h\u0131zl\u0131 bir \u015fekilde gerilemeye ba\u015flad\u0131\u011f\u0131 \u00f6nemli bir d\u00f6neme odaklanacak\u201c dedi. \u201dBu y\u0131k\u0131c\u0131 hastal\u0131k i\u00e7in tedavi se\u00e7enekleri s\u0131n\u0131rl\u0131 kalmaya devam ediyor ve bu \u00e7al\u0131\u015fma, Duchenne hastas\u0131 \u00e7ocuklarda kas yenilenmesini potansiyel olarak art\u0131rarak fonksiyonu iyile\u015ftirebilecek yeni bir yakla\u015f\u0131m\u0131 de\u011ferlendirecek.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">SAT-3247 nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247, Duchenne kas distrofisi ve di\u011fer dejeneratif veya yaralanma durumlar\u0131nda kaybedilen iskelet kas\u0131n\u0131 yenilemek i\u00e7in yeni bir tedavi olarak Satellos taraf\u0131ndan geli\u015ftirilen, tescilli, oral, k\u00fc\u00e7\u00fck molek\u00fcll\u00fc bir ila\u00e7t\u0131r. Satellos, distrofinden ba\u011f\u0131ms\u0131z ve ekson mutasyon durumundan ba\u011f\u0131ms\u0131z olarak, SAT-3247&#039;yi DMD i\u00e7in potansiyel bir tedavi olarak geli\u015ftirmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu Sayfay\u0131 Takip Edin<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne i\u00e7in T\u00fcm Klinik Ara\u015ft\u0131rmalar<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos Bioscience announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy (\u201cDuchenne\u201d or \u201cDMD\u201d). The study will evaluate SAT-3247 in 51 ambulatory children with DMD aged 7, 8 or 9 years of age. Primary endpoints include safety, tolerability [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6208,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[303,137,242,254,251,252,253],"class_list":["post-6207","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-cell-therapy","tag-clinical-trial","tag-clinical-trials","tag-frank-gleeson","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/6207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=6207"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/6207\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/6208"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=6207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=6207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=6207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}